Your browser doesn't support javascript.
loading
Outcomes following bioprosthetic valve replacement in prior non-cardiac transplant recipients.
Bozso, Sabin J; Kang, Jimmy J H; Al-Adra, David; Hong, Yongzhe; Moon, Michael C; Freed, Darren H; Nagendran, Jayan; Nagendran, Jeevan.
Affiliation
  • Bozso SJ; Division of Cardiac Surgery, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
  • Kang JJH; Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
  • Al-Adra D; Department of Surgery, Division of Transplantation, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
  • Hong Y; Division of Cardiac Surgery, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
  • Moon MC; Division of Cardiac Surgery, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
  • Freed DH; Division of Cardiac Surgery, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
  • Nagendran J; Alberta Transplant Institute, Edmonton, Alberta, Canada.
  • Nagendran J; Canadian Transplant Research Program, Edmonton, Alberta, Canada.
Clin Transplant ; 33(11): e13720, 2019 11.
Article in En | MEDLINE | ID: mdl-31556148
ABSTRACT

BACKGROUND:

We report on overall survival and valve-related outcomes after bioprosthetic valve replacement in prior transplant recipients.

METHODS:

From January 2004 to December 2018, 20 consecutive patients (mean age 65.7-years, 90% male) with prior non-cardiac transplantation underwent bioprosthetic aortic (n = 18) or combined aortic and mitral (n = 2) valve replacement. Patients consisted of kidney (n = 14), lung (n = 2), liver (n = 3), and bone-marrow (n = 2) transplants with the most common indication for valve replacement being calcific degeneration (n = 12). Outcomes were measured over a 12-year span, with a median follow-up duration of 3.9 years.

RESULTS:

Overall survival at 30 days was 100% and at median follow-up was 60%. Acute kidney injury occurred in 50% (n = 10) with temporary dialysis required in 5% (n = 1) and 15% (n = 3) suffered respiratory failure. No patients experienced major bleeding, heart failure, or sternal wound infection. No patients required redo valve replacement during the study period.

CONCLUSIONS:

Our results provide contemporary data demonstrating that patients with prior transplant can undergo bioprosthetic valve replacement with acceptable inhospital mortality rates and long-term survival, with a low rate of major morbidity. Furthermore, bioprosthetic valve replacement is a viable option in this group of patients with no redo valve replacement and acceptable long-term hemodynamic valvular function.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bioprosthesis / Heart Valve Prosthesis Implantation / Graft Survival / Heart Valve Diseases Type of study: Observational_studies / Prognostic_studies Limits: Aged / Female / Humans / Male Language: En Journal: Clin Transplant Journal subject: TRANSPLANTE Year: 2019 Type: Article Affiliation country: Canada

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bioprosthesis / Heart Valve Prosthesis Implantation / Graft Survival / Heart Valve Diseases Type of study: Observational_studies / Prognostic_studies Limits: Aged / Female / Humans / Male Language: En Journal: Clin Transplant Journal subject: TRANSPLANTE Year: 2019 Type: Article Affiliation country: Canada